Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Plant Allergenic Extract [EPC]
Blastocystis Hominis is a non-standardized allergenic extract used primarily in diagnostic medicine and immunotherapy. It belongs to classes including fungal and plant allergenic extracts, utilized to identify and manage specific hypersensitivity reactions.
Name
Blastocystis Hominis
Raw Name
BLASTOCYSTIS HOMINIS
Category
Non-Standardized Plant Allergenic Extract [EPC]
Drug Count
6
Variant Count
6
Last Verified
February 17, 2026
About Blastocystis Hominis
Blastocystis Hominis is a non-standardized allergenic extract used primarily in diagnostic medicine and immunotherapy. It belongs to classes including fungal and plant allergenic extracts, utilized to identify and manage specific hypersensitivity reactions.
Detailed information about Blastocystis Hominis
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Blastocystis Hominis.
Blastocystis Hominis, in its clinical pharmaceutical form, is classified as a Non-Standardized Allergenic Extract. While the name refers to a common microscopic protozoan parasite found in the human digestive tract, the pharmaceutical application involves the use of purified antigenic proteins derived from the organism. According to the FDA's Electronic Physician Codification (EPC), it is categorized under multiple classes including Non-Standardized Plant Allergenic Extract, Non-Standardized Food Allergenic Extract, and Non-Standardized Fungal Allergenic Extract. Intriguingly, it is also associated with the Penicillin-class Antibacterial [EPC] designation in specific regulatory contexts, often relating to cross-reactivity assessments or manufacturing markers.
As a non-standardized extract, the potency of Blastocystis Hominis is not measured against a national standard of reference. Instead, it is prepared through rigorous aqueous extraction processes designed to capture the immunogenic profile of the organism. This drug belongs to a class of agents used for the diagnosis and treatment of Type I hypersensitivities (immediate-type allergic reactions). The FDA-approved history of allergenic extracts dates back several decades, with Blastocystis Hominis extracts serving a niche role in identifying patients who may exhibit idiosyncratic immune responses to this specific protozoan or related environmental antigens.
The mechanism of action for Blastocystis Hominis extract is rooted in the fundamental principles of immunology. When used for diagnostic purposes, such as skin prick testing (SPT), the extract is introduced into the epidermis. If the patient has been previously sensitized to Blastocystis Hominis antigens, their immune system will have produced specific Immunoglobulin E (IgE) antibodies. These IgE antibodies are bound to the surface of mast cells and basophils.
Upon exposure to the extract, the antigens bind to the IgE antibodies, causing 'cross-linking.' This molecular event triggers the degranulation of mast cells, leading to the release of inflammatory mediators, most notably histamine, leukotrienes, and prostaglandins. This results in the 'wheal and flare' reaction—a localized area of swelling (wheal) and redness (flare)—which confirms the presence of hypersensitivity. In the context of immunotherapy (allergy shots), the repeated administration of gradually increasing doses of the extract works by shifting the immune response from a Th2-dominant (allergic) profile to a Th1-dominant profile, increasing the production of 'blocking' IgG4 antibodies and reducing IgE-mediated sensitivity.
Because Blastocystis Hominis is typically administered via the epicutaneous (skin) or subcutaneous route, its pharmacokinetic profile differs significantly from oral medications.
Blastocystis Hominis extract is primarily utilized in two clinical scenarios:
Blastocystis Hominis is generally available in the following forms:
> Important: Only your healthcare provider can determine if Blastocystis Hominis is right for your specific condition. The use of allergenic extracts must be conducted under the supervision of a clinician trained in the management of anaphylaxis.
Dosage for Blastocystis Hominis is highly individualized and depends entirely on the method of administration and the patient's sensitivity levels.
Blastocystis Hominis extracts may be used in children; however, the testing surface (the back or forearm) must be large enough to accommodate the test and controls. Dosage volumes are generally the same as adults, but the number of simultaneous tests may be limited to prevent excessive systemic absorption or patient distress. Safety and efficacy in infants under 6 months of age have not been established.
No specific dose adjustments are required for renal impairment, as the systemic protein load is minimal. However, patients with end-stage renal disease should be monitored for altered skin reactivity.
No dosage adjustments are necessary for patients with liver disease.
Elderly patients may have reduced skin turgor and reactivity, potentially leading to false-negative results in diagnostic testing. Healthcare providers should interpret results with caution in patients over 65.
Blastocystis Hominis extracts are never for self-administration or oral use. They must be administered by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment.
In the context of immunotherapy, a missed dose can increase the risk of an adverse reaction when treatment resumes. If a dose is missed by more than one week, the healthcare provider may need to reduce the next dose to ensure safety. If testing is missed, it can be rescheduled at any time, provided the patient has not taken interfering medications like antihistamines.
An overdose of Blastocystis Hominis extract typically occurs through accidental injection of a concentration higher than intended. Signs of overdose include:
In the event of an overdose or systemic reaction, epinephrine (1:1000) must be administered intramuscularly immediately, and emergency services must be contacted.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to use these extracts without direct medical guidance.
Most patients receiving Blastocystis Hominis extract for diagnostic purposes will experience local reactions at the site of administration. These are typically expected and indicate the test is working.
> Warning: Stop taking Blastocystis Hominis and call your doctor immediately if you experience any of these.
Because Blastocystis Hominis extract is used intermittently for testing or in very small doses for immunotherapy, long-term systemic side effects are virtually non-existent. There is no evidence that long-term use leads to organ toxicity or malignancy. The primary long-term risk is the potential for increased sensitivity if immunotherapy is not managed correctly.
Blastocystis Hominis extract can cause severe, life-threatening systemic allergic reactions, including anaphylaxis. This product must only be administered by healthcare professionals prepared to manage such reactions. Patients with unstable asthma or those taking beta-blockers may be at increased risk for severe outcomes or may be resistant to standard rescue treatments like epinephrine. Patients must be observed for at least 30 minutes following any injection.
Report any unusual symptoms to your healthcare provider immediately. Even a mild systemic reaction (like itching of the palms or throat) can be a precursor to a more severe event.
Blastocystis Hominis extract is a potent biological substance. It is only intended for use by specialists in allergy and immunology. Patients must provide a full medical history, specifically focusing on previous reactions to vaccines, insect stings, or other allergenic extracts. It is vital to understand that 'non-standardized' means the potency can vary between different manufacturers or even different lots, requiring cautious 'bridging' when switching vials.
No FDA black box warnings are uniquely assigned to Blastocystis Hominis specifically, but it falls under the general class warning for all Allergenic Extracts. This warning emphasizes the risk of anaphylaxis and the requirement for administration in a controlled clinical setting. The full text stresses that epinephrine must be immediately available and that the patient must be monitored for a minimum of 30 minutes post-administration.
Generally, Blastocystis Hominis does not affect the ability to drive. However, if a patient experiences a vasovagal reaction (fainting) or a systemic allergic reaction, they should not drive until cleared by a medical professional.
Alcohol consumption should be avoided for 24 hours before and after administration. Alcohol can increase peripheral vasodilation, which may accelerate the absorption of the extract or worsen the severity of a local or systemic reaction.
If a patient develops a systemic reaction, the use of the extract must be discontinued immediately. A thorough re-evaluation of the risk-benefit profile is required before any further administration. For immunotherapy, if the patient becomes pregnant, the dose is typically not increased, though it may be maintained if already at a stable level.
> Important: Discuss all your medical conditions with your healthcare provider before starting Blastocystis Hominis.
While there are few absolute contraindications for drug combinations, certain drugs make the use of Blastocystis Hominis extract extremely dangerous:
Blastocystis Hominis extract does not interfere with standard blood chemistry or hematology tests. However, it will directly affect the results of an Allergy Skin Test Panel. It may also cause a temporary increase in total serum IgE or specific IgE levels if measured shortly after a large-dose immunotherapy injection.
For each major interaction, the primary strategy is pre-treatment screening. Doctors will use a 'medication wash-out' period:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Blastocystis Hominis must NEVER be used in the following circumstances:
Patients allergic to certain fungi or other protozoal antigens may exhibit cross-sensitivity to Blastocystis Hominis. Because it is categorized as a Non-Standardized Fungal and Plant extract, there is a theoretical risk for patients with known severe mold or yeast allergies to react more strongly to this extract.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing or administering Blastocystis Hominis.
Blastocystis Hominis is classified as FDA Pregnancy Category C. This means animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm. The primary risk during pregnancy is not the extract itself, but the potential for maternal anaphylaxis. Anaphylaxis can cause a sudden drop in maternal blood pressure, leading to placental hypoperfusion and fetal hypoxia (lack of oxygen). Therefore, skin testing is typically deferred until postpartum.
It is not known whether the antigenic components of Blastocystis Hominis are excreted in human milk. However, because these are large proteins administered in minute quantities, systemic absorption is low, and the risk to a nursing infant is considered minimal. Healthcare providers usually consider it safe to continue maintenance immunotherapy while breastfeeding.
Allergenic extracts are used in children as young as toddlers, but the procedure requires significant cooperation. In children, the risk of a systemic reaction is similar to adults, but they may be less able to communicate early symptoms like an itchy throat or a 'funny taste' in the mouth. Close clinical observation is mandatory.
In patients over 65, skin reactivity decreases due to the natural aging of the immune system and changes in skin structure. This increase the likelihood of false-negative results. Additionally, elderly patients are more likely to be on medications (like beta-blockers or ACE inhibitors) that complicate the management of adverse reactions.
Patients with chronic kidney disease may have altered skin responses (uremic pruritus), which can interfere with the interpretation of diagnostic tests. No specific dose adjustments are required, but the clinician must be aware of the patient's baseline skin irritability.
There are no known issues with using Blastocystis Hominis in patients with liver disease. The metabolism of the proteins is handled by local and systemic proteases, not the cytochrome P450 system of the liver.
> Important: Special populations require individualized medical assessment and a cautious approach to diagnostic immunology.
Blastocystis Hominis extract acts as an exogenous antigen. At the molecular level, the proteins in the extract contain specific epitopes (binding sites) that are recognized by the Fab portion of IgE antibodies. These IgE antibodies are 'sensitized' and attached to high-affinity FcεRI receptors on mast cells. When the extract is introduced, it cross-links these receptors, triggering a signal transduction cascade involving tyrosine kinases (like Syk). This leads to an influx of calcium ions and the subsequent exocytosis (release) of pre-formed mediators like histamine.
| Parameter | Value |
|---|---|
| Bioavailability | Negligible (Epicutaneous) |
| Protein Binding | N/A (Local action) |
| Half-life | Minutes to hours (Proteolysis) |
| Tmax | 15–20 minutes (for local reaction) |
| Metabolism | Tissue Proteases |
| Excretion | Renal (as amino acids) |
Blastocystis Hominis is part of the Allergenic Extract therapeutic class. It is specifically grouped under non-standardized extracts, distinguishing it from 'Standardized' extracts like those for Grass Pollen or Dust Mites, which have defined Bioequivalent Allergy Units (BAU).
Medications containing this ingredient
Common questions about Blastocystis Hominis
Blastocystis Hominis extract is primarily used as a diagnostic tool in allergy medicine to identify if a patient has a specific sensitivity to this organism. It is often employed when a patient has unexplained chronic hives or digestive issues that may be linked to an immune response against the parasite. By applying a small amount to the skin, doctors can observe if an allergic 'wheal and flare' reaction occurs. In some specialized cases, it may also be used in immunotherapy to help desensitize a patient over time. However, its use is quite specific and determined only by an allergy specialist.
The most common side effects are localized to the area where the extract was applied or injected. Patients typically experience itching, redness, and a small raised bump known as a wheal, which looks similar to a mosquito bite. These symptoms are actually the intended result of a diagnostic test and usually fade within an hour or two. Some patients may also experience a 'late-phase' reaction where swelling returns several hours later. Systemic side effects are rare but can include hives on other parts of the body or a mild feeling of tiredness.
It is strongly recommended to avoid alcohol for at least 24 hours before and after receiving Blastocystis Hominis extract. Alcohol causes the blood vessels to dilate (expand), which can increase the blood flow to the skin and potentially make a local reaction more severe or unpredictable. Furthermore, alcohol can increase the speed at which the extract is absorbed into the bloodstream, slightly raising the risk of a systemic allergic reaction. Alcohol may also interfere with your ability to recognize early symptoms of a serious reaction. Always follow your doctor's specific pre-test instructions regarding diet and lifestyle.
The use of Blastocystis Hominis extracts is generally avoided during pregnancy, especially for new diagnostic testing or starting new immunotherapy. While the extract itself is not known to be toxic to the fetus, the risk of a severe allergic reaction (anaphylaxis) in the mother is a significant concern. Anaphylaxis can cause a dangerous drop in blood pressure, which may deprive the developing baby of oxygen. If a woman is already on a stable maintenance dose of immunotherapy and becomes pregnant, her doctor may choose to continue the treatment but will not increase the dose. Most doctors prefer to wait until after delivery to perform any allergy skin testing.
For diagnostic purposes, Blastocystis Hominis works very quickly, with results typically appearing within 15 to 20 minutes of the skin prick test. This is because it triggers an 'immediate-type' hypersensitivity reaction. If you are receiving the extract as part of immunotherapy, the process is much slower and can take several months to a year before you notice a reduction in allergy symptoms. Immunotherapy requires a 'build-up phase' where the dose is gradually increased. You must be patient and consistent with your appointments to see the long-term benefits of desensitization.
Since Blastocystis Hominis is usually administered as a one-time diagnostic test or as a long-term series of allergy shots, 'stopping' it does not cause withdrawal symptoms like some other medications. However, if you are in the middle of an immunotherapy program and stop suddenly, you will lose the progress made toward desensitization, and your allergies may return to their previous severity. If you miss several doses, you cannot simply restart at the same level; your doctor will need to lower the dose and gradually build it back up to ensure your safety. Always discuss your schedule with your allergist before interrupting treatment.
If you miss an appointment for a Blastocystis Hominis immunotherapy injection, contact your allergist's office as soon as possible to reschedule. The safety of the next dose depends on how much time has passed since your last injection. If only a few extra days have passed, you may be able to continue as normal. However, if you miss your dose by more than a week, your doctor may need to reduce the amount of extract in your next shot to prevent an adverse reaction. Never try to 'double up' on doses to make up for a missed one, as this significantly increases the risk of anaphylaxis.
There is no clinical evidence to suggest that Blastocystis Hominis extract causes weight gain. The medication is a protein-based extract administered in very small quantities, either on the skin or under the skin, and it does not affect the metabolic processes or hormones that regulate body weight. If you experience weight changes while undergoing allergy testing or treatment, it is likely due to other factors, such as changes in diet, exercise, or other medications you may be taking (like oral steroids). If you have concerns about your weight, you should discuss them with your primary care physician.
Blastocystis Hominis can interact with several other medications, which is why a full disclosure of your current drugs is necessary. The most important interactions are with antihistamines, which can block the test results, and beta-blockers, which can make it difficult to treat an allergic reaction if one occurs. Other medications like antidepressants (TCAs) and certain blood pressure heart medicines (ACE inhibitors) can also interfere with the safety or accuracy of the treatment. Your doctor will provide a specific list of medications to avoid in the days leading up to your appointment. Always check with your pharmacist before starting any new over-the-counter drugs during treatment.
Allergenic extracts like Blastocystis Hominis are biological products rather than simple chemical drugs, so the term 'generic' is not used in the same way. Instead, there are various manufacturers that produce 'non-standardized' versions of the extract. While these products are similar, they are not considered identical or interchangeable. If your doctor starts your treatment with an extract from one manufacturer, they will typically try to keep you on that same brand for the duration of your testing or treatment. If a switch is necessary, the doctor will often reduce the dose initially to ensure your immune system handles the new extract safely.